Offer Update
June 02 2003 - 3:33AM
UK Regulatory
RNS Number:7842L
Protherics PLC
02 June 2003
Protherics PLC
Recommended Offer for Enact Pharma plc ("Enact")
Results of Placing and Open Offer
On 2 May 29003 Protherics PLC (the "Company" or "Protherics") announced a
recommended offer for all the issued and to be issued share capital of Enact,
and a Placing and Open Offer of up to 18,804,468 new Ordinary Shares of 2 pence
each at 16 pence per share to raise approximately #3 million (before expenses),
of which up to 9,411,646 new ordinary shares have been placed with institutional
investors subject to recall to satisfy valid applications under the Open Offer
(the "Open Offer Shares") and 9,392,822 new Ordinary Shares have been placed
firm with institutional investors (the "Firm Placed Shares").
As announced on 29 May 2003 the recommended offer to acquire the entire issued
and to be issued share capital of Enact has been declared unconditional as to
acceptances.
The Open Offer to Qualifying Shareholders of up to 9,411,646 Open Offer Shares
at 16 pence per share closed at 3.00 p.m. on Friday 30 May 2003. Valid
applications were received in respect of 4,961,127 new Ordinary Shares ,
representing 52.7 per cent. of the Open Offer Shares.
The remaining 4,448,535 Open Offer Shares and the 9,392,822 Firm Placed Shares
(constituting a total of 13,841,357 new Ordinary Shares) will be taken up by
institutional investors pursuant to the Placing by WestLB Panmure Limited.
The Placing and Open Offer remains conditional upon admission of the new
Ordinary Shares to the Official List of the London Stock Exchange.
Application has been made to the UK Listing Authority for the new Ordinary
Shares to be admitted to the Official List and to the London Stock Exchange for
admission to trading. The 18,802,484 new Ordinary Shares are expected to be
admitted to the Official List at 8.00 a.m. on 4 June 2003. CREST stock accounts
are expected to be credited on 4 June 2003 and definitive share certificates in
respect of the new Ordinary Shares are expected to be despatched, where
applicable, by 11 June 2003.
2 June 2003
Enquiries:
Protherics PLC 020 7246 9950
Andrew Heath, Chief Executive
Barry Riley, Finance Director
WestLB Panmure Limited 020 7020 4000
Juliet Thompson
The Maitland Consultancy 020 7379 5151
Brian Hudspith
Simone Cheetham
This information is provided by RNS
The company news service from the London Stock Exchange
END
OUPGIGDLGXGGGXD